All individual trials at Rain Oncology Inc

An AllTrials project

All individual trials at Rain Oncology Inc

3 out of 5

60.0%

$46,727,191

$0

Status	Sponsor	Trial ID	Title	Completion date	Days overdue
overdue	Rain Oncology Inc	NCT02454842	A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor [pACT]	2017-01-31	1888
overdue	Rain Oncology Inc	NCT02449681	A Phase 2 Study of Tarloxotinib (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin [pACT]	2017-01-31	1888
reported-late	Rain Oncology Inc	NCT03805841	Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions	2021-04-09	353
reported	Rain Oncology Inc	NCT04979442	A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients With Dedifferentiated Liposarcoma	2023-10-01
reported	Rain Oncology Inc	NCT05012397	A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)	2023-10-15

Download this data